Pivotal readout
UCB's bimekizumab keeps its edge over risankizumab in psoriatic arthritis at week 24
In BE BOLD, a Phase 3b head-to-head study, 54.9% of patients on Bimzelx reached ACR50 at week 24, compared with 43.8% on Skyrizi, extending the superiority shown at week 16. The top-ranked secondary endpoint missed significance, and complete skin clearance was about equal. Localized Candida infections were more common with Bimzelx, and full results go to ACR Convergence.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.
